| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05435053 2020-004623-17 Details | 2023-09-15 Interventional | 2 | 9 | Nivolumab Pancreatic Neop… Pancreas Cancer | The study was terminated on the basis on an evaluation of the safety and efficacy of the 9
included patients of which 2 of the patients were excluded before receiving any study
treatments, thus 7 patients were treated in the study. - | |||
| NCT04780269 Details | 2023-09-15 Interventional | 4 | - | Dinoprostone Induced Deliver… Labor Induction | understaffed - | |||
| NCT04536363 Details | 2023-09-15 Interventional | 2 | 0 | Alprostadil COVID-19 Covid19 | Delays in approval by the national regulatory authority - | |||
| NCT04328714 Details | 2023-09-15 Interventional | 1 | - | Interferon-gamm… Interferons Myelodysplastic… Acute Leukemia | Study is suspended pending renovation and reopening of the facility manufacturing the study
product. - | |||
| NCT03854500 2018-003090-95 Details | 2023-09-15 Interventional | 3 | 201 | Tenecteplase Tissue Plasmino… Cerebrovascular… Ischemic Stroke Stroke Stroke, Acute | Per protocol safety analysis 200 patients showed a significant difference in bleeding rates
between the two drug groups. - | |||
| NCT05994183 Details | 2023-09-14 Interventional | 1 | 0 | Dexamethasone Bronchiolitis | The study was withdrawn with no participants enrolled due to the need for an IND from the FDA,
which significantly expanded the scope of the study beyond what was originally anticipated for
a pilot project within this network. - | |||
| NCT05394350 2021-006712-93 Details | 2023-09-14 Interventional | 1/2 | 27 | Pembrolizumab Neoplasms Advanced Solid … | Business Reasons - | |||
| NCT04499235 Details | 2023-09-14 Interventional | 2 | 6 | Mometasone Furo… Pemphigoid, Bul… | The study was prematurely terminated by the Sponsor due to operational challenges stemming from
the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease,
and drug supply considerations. - | |||
| NCT01996605 Details | 2023-09-14 Interventional | 2 | 20 | Oxytocin Healthy Volunte… | Cessation of funding period prior to completion, due to slow recruitment during the pandemic The study was powered for a sample size of 40 and was terminated early with a sample size of 20 due to slow recruitment and cessation of financial support. | |||
| NCT05535023 Details | 2023-09-13 Interventional | 2 | 0 | Cemiplimab Carcinoma Carcinoma, Squa… Oropharyngeal N… Head and Neck C… Oropharynx Canc… Squamous Cell C… | PI Request - | |||
| NCT05315479 Details | 2023-09-13 Interventional | 4 | 19 | Meloxicam Pain, Postopera… Post Operative … | Anjeso (N1539) NDA Withdrawn - | |||
| NCT05243524 Details | 2023-09-13 Interventional | 2 | 16 | Cyclophosphamid… Carcinoma, Ovar… Ovarian Neoplas… Platinum-resist… | Closure of IMV operations - | |||
| NCT04834349 Details | 2023-09-13 Interventional | 2 | 0 | Pembrolizumab Carcinoma Carcinoma, Squa… Recurrence Squamous Cell C… Recurrent Head … Unresectable He… | No participants were enrolled - | |||
| NCT04749797 Details | 2023-09-13 Interventional | 4 | 11 | Bupivacaine Craniotomy Surg… | PI left institution Study concluded before reaching subject n goal due to slow enrollment related to COVID-19 pandemic and PI leaving institution. Sample size not significant enough to accurately analyze data. | |||
| NCT04485130 Details | 2023-09-13 Interventional | 2 | 11 | Disulfiram COVID-19 Covid19 | Low COVID case numbers, competing COVID treatments available - | |||
| NCT04458948 Details | 2023-09-13 Interventional | 2 | 28 | Azithromycin Hydroxychloroqu… COVID-19 | The World Health Organization (WHO) paused Hydrochloroquinone from its Solidarity Trial in
order to conduct a safety data review by the Data Safety Monitoring Board of the WHO to
evaluate HCQ in its clinical trials. - | |||
| NCT04208516 Details | 2023-09-13 Interventional | 4 | 17 | Dexamethasone Dexmedetomidine Lidocaine Ropivacaine Pain, Postopera… Postoperative P… | Recruitment was unable to be obtained in a timely fashion, so the study was stopped. We were not able to enroll enough subjects in a timely manner and our enrollment numbers did not reach the goal of our pilot study. | |||
| NCT04181255 Details | 2023-09-13 Interventional | 1 | 2 | Poractant alfa Heart Defects, … Heart Diseases Hypoplastic Lef… Congenital Hear… | Investigator Retirement - | |||
| NCT04079738 Details | 2023-09-13 Interventional | 1/2 | 8 | Ixazomib AML AML, Adult | Funder requested termination due to halting internal development of TAK-659 - | |||
| NCT03860207 Details | 2023-09-13 Interventional | 1/2 | 12 | Antibodies Antibodies, Bis… Immunoglobulins Neuroblastoma Osteosarcoma Other Solid Tum… | study terminated due to business priorities The study was terminated after 11 subjects due to a business strategy decision. At this point the maximum tolerated dose was not established. |